Complex role of tumor cell transforming growth factor (TGF)-βs on breast carcinoma progression

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Journal of mammary gland biology and neoplasia

• Publication date

  1996-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF02017393PMID 10887511
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transforming Growth Factor‐ β Type II Receptor Is Infrequently Expressed in Human Breast Cancer

  1996cited by this paper
• Transforming growth factor-β in in vivo resistance

  1996cited by this paper
• Transforming growth factor-beta in in vivo resistance.

  1996cited by this paper
• 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells.

  1995cited by this paper
• Drug Resistance and Gene Amplification Potential Regulated by Transforming Growth Factor β1 Gene Expression

  1995cited by this paper
• Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen.

  1995cited by this paper
• Mammary tumor suppression by transforming growth factor beta 1 transgene expression.

  1995cited by this paper
• Drug resistance and gene amplification potential regulated by transforming growth factor beta 1 gene expression.

  1995cited by this paper
• GH3 Pituitary Tumor Cells Contain Heteromeric Type I and Type II Receptor Complexes for Transforming Growth Factor and Activin-A (*)

  1995cited by this paper
• Effects of TGF‐β1 (transforming growth factor‐β1) on the cell cycle regulation of human breast adenocarcinoma (MCF‐7) cells

  1995cited by this paper
• Signaling by the transforming growth factor-β receptor

  1995cited by this paper
• Signaling by the transforming growth factor-beta receptors.

  1995cited by this paper
• Transforming Growth Factor β2 (TGF-β2) Levels in Plasma of Patients with Metastatic Breast Cancer Treated with Tamoxifen

  1995cited by this paper
• Effects of TGF-beta 1 (transforming growth factor-beta 1) on the cell cycle regulation of human breast adenocarcinoma (MCF-7) cells.

  1995cited by this paper
• Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines.

  1995cited by this paper
• Thrombospondin and transforming growth factor‐beta 1 increase expression of urokinase‐type plasminogen activator and plasminogen activator inhibitor‐1 in human MDA‐MB‐231 breast cancer cells

  1995cited by this paper
• The role of TGF‐β production in growth inhibition of breast‐tumor cells by progestins

  1995cited by this paper
• Absence of transforming growth factor-beta responsiveness in the tamoxifen growth-inhibited human breast cancer cell line CAMA-1.

  1994cited by this paper
• Expression of transforming growth factor beta mRNA isoforms in human breast cancer.

  1994cited by this paper
• Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma.

  1994cited by this paper
• Alterations in transforming growth factor-alpha and -beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth.

  1994cited by this paper
• Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells

  1994cited by this paper
• Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells.

  1994cited by this paper
• Immune dysregulation in TGF-beta 1-deficient mice.

  1994cited by this paper
• Alterations in Transforming Growth Factor-α and -β Production and Cell Responsiveness during the Progression of MCF-7 Human Breast Cancer Cells to Estrogen-Autonomous Growth

  1994cited by this paper
• Regulation of the levels of three transforming growth factor beta mRNAs by estrogen and their effects on the proliferation of human breast cancer cells.

  1993cited by this paper
• Pleiotropic Effects of Transforming Growth Factor‐β on Cells of the Immune System

  1993cited by this paper
• Regulation of the levels of three transforming growth factor β mRNAs by estrogen and their effects on the proliferation of human breast cancer cells

  1993cited by this paper
• Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro.

  1993cited by this paper
• Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities.

  1993cited by this paper
• Extracellular matrix regulates expression of the TGF-beta 1 gene

  1993cited by this paper
• Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma.

  1993cited by this paper
• Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice.

  1993cited by this paper
• TGF-β gene expression depends on tissue architecture

  1993cited by this paper
• TGFβ induction of extracellular matrix associated proteins in normal and transformed human mammary epithelial cells in culture is independent of growth effects

  1993cited by this paper
• TGF alpha and TGF beta expression in mammary carcinoma

  1993cited by this paper
• Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.

  1993cited by this paper
• TGF-beta gene expression depends on tissue architecture.

  1993cited by this paper
• p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

  1993cited by this paper
• Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1.

  1993cited by this paper
• Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast.

  1992cited by this paper
• Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease

  1992cited by this paper
• Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer.

  1992cited by this paper
• Induction of Transforming Growth Factor β1 in Human Breast Cancer in Vivo following Tamoxifen Treatment

  1992cited by this paper
• Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment.

  1992cited by this paper
• Localization of transforming growth factor-beta isotypes in lesions of the human breast.

  1992cited by this paper
• The Transforming Growth Factor-βs

  1991cited by this paper
• Interleukin 1, interleukin 6, tumor necrosis factor, and transforming growth factor beta increase cell resistance to tumor necrosis factor cytotoxicity by growth arrest in the G1 phase of the cell cycle.

  1991cited by this paper
• The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta.

  1991cited by this paper
• Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer.

  1991cited by this paper
• Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells.

  1991cited by this paper
• Growth stimulation and differential regulation of transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, and TGF beta 3 messenger RNA levels by norethindrone in MCF-7 human breast cancer cells.

  1991cited by this paper
• Growth Stimulation and Differential Regulation of Transforming Growth Factor-β1 (TGFβ1), TGFβ2, and TGFβ3 Messenger RNA Levels by Norethindrone in MCF-7 Human Breast Cancer Cells

  1991cited by this paper
• Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice.

  1991cited by this paper
• Transforming growth factor β stimulates mamary adenocarcinoma cell invasion and metastasis potential

  1990cited by this paper
• The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA.

  1990cited by this paper
• Interaction of growth factors during progression towards steroid independence in T‐47‐D human breast cancer cells

  1990cited by this paper
• Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I and neu oncogene product in benign and malignant human breast tissues.

  1990cited by this paper
• Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta.

  1990cited by this paper
• Role of bone marrow transplantation as treatment for victims of nuclear accidents.

  1990cited by this paper
• Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential.

  1990cited by this paper
• Differential regulation of expression of three transforming growth factor beta species in human breast cancer cell lines by estradiol.

  1990cited by this paper
• Transcripts for transforming growth factors in human breast cancer: clinical correlates.

  1990cited by this paper
• Approaches to studying the role of growth factors in the progression of breast tumours from the steroid sensitive to insensitive state.

  1989cited by this paper
• Production of and responsiveness to transforming growth factor-beta in normal and oncogene-transformed human mammary epithelial cells.

  1989cited by this paper
• Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines.

  1989cited by this paper
• Transforming growth factors type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines

  1989cited by this paper
• Expression of growth factors and oncogenes in normal and tumor-derived human mammary epithelial cells.

  1988cited by this paper
• Transforming growth factor β: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells

  1988cited by this paper
• Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells.

  1988cited by this paper
• Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells.

  1987cited by this paper
• Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene.

  1987cited by this paper
• Complementary DNA for human glioblastoma‐derived T cell suppressor factor, a novel member of the transforming growth factor‐beta gene family.

  1987cited by this paper
• Characterization of estrogen responsive transforming activity in human breast cancer cell lines.

  1986cited by this paper
• Transforming growth factor production by chemically transformed cells.

  1981cited by this paper
• New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues.

  1981cited by this paper
• ALLERGIC INFLAMMATION. II. IDENTIFICATION OF ANTIGEN-ANTIBODY COMPLEXES WITH THE ELECTRON MICROSCOPE DURING THE EARLY PHASE OF ALLERGIC INFLAMMATION.

  1963cited by this paper

• Cellular Potts Modeling of Tumor Growth, Tumor Invasion, and Tumor Evolution

  2013cites this paper
• Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?

  2013cites this paper
• Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies? Ursini-Siegel*

  2013cites this paper
• Inhibition of TGF-β Enhances the In Vivo Antitumor Efficacy of EGF Receptor–Targeted Therapy

  2012cites this paper
• Decoy Receptor 3 Overexpression and Immunologic Tolerance in Hepatocellular Carcinoma (HCC) Development

  2008cites this paper
• Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy.

  2007cites this paper
• Estrogen receptors inhibit Smad3 transcriptional activity through Ap-1 transcription factors

  2007cites this paper
• Transforming growth factor-beta1 genotype in sporadic breast cancer patients from India: status of enhancer, promoter, 5'-untranslated-region and exon-1 polymorphisms.

  2004cites this paper
• Tamoxifen treatment failure in cancer and the nonlinear dynamics of TGFbeta.

  2004influential citation
• Role of transforming growth factor beta in breast carcinogenesis.

  2004cites this paper
• Synergy between anti‐endoglin (CD105) monoclonal antibodies and TGF‐β in suppression of growth of human endothelial cells

  2004cites this paper
• Role of transforming growth factor in breast carcinogenesis

  2004cites this paper
• The TGFβ inducible early gene plays a central role in the anti-proliferative response to TGFβ

  2004cites this paper
• Role of transforming growth factorin breast carcinogenesis

  2004cites this paper
• Growth factor-binding sequence in human alpha2-macroglobulin targets the receptor-binding site in transforming growth factor-beta.

  2003cites this paper
• Regulation of G1/S Cell Cycle Progression by Transforming Growth Factor-beta

  2003cites this paper
• Expression of latent TGF-beta binding protein LTBP-1 is hormonally regulated in normal and transformed human lung fibroblasts.

  2003cites this paper
• Breast Cancer Biology

  2003cites this paper
• Interference with TGF‐β1 and ‐β3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma

  2002cites this paper
• Consequences of altered TGF-β expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects

  2002cites this paper
• Transcriptional regulation of Smad2 is required for enhancement of TGFbeta/Smad signaling by TGFbeta inducible early gene.

  2002cites this paper
• Hormone/growth factor interactions mediating epithelial/stromal communication in mammary gland development and carcinogenesis.

  2002cites this paper
• Responsiveness to transforming growth factor-beta (TGF-beta)-mediated growth inhibition is a function of membrane-bound TGF-beta type II receptor in human breast cancer cells.

  2001cites this paper
• Conditioned Medium From MCF-7 Cell Line Induces Myofibroblast Differentiation, Decreased Cell Proliferation, and Increased Apoptosis in Cultured Normal Fibroblasts but not in Fibroblasts from Malignant Breast Tissue

  2001cites this paper
• TGF‐β–induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase‐2 and the urokinase plasminogen activator system

  2001cites this paper
• Muc4/Sialomucin Complex in the Mammary Gland and Breast Cancer

  2001cites this paper
• Serum levels of transforming growth factor beta1 in patients with breast cancer.

  2001cites this paper
• Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.

  2001cites this paper
• Transforming growth factor-β and breast cancer: Lessons learned from genetically altered mouse models

  2000cites this paper
• The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach.

  2000cites this paper
• Differential expression of and responsiveness to transforming growth factor-beta (TGF-beta) isoforms in hormone-dependent and independent lines of mouse mammary tumors.

  1999cites this paper
• Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.

  1999cites this paper
• Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy.

  1998cites this paper
• Blockade of Transforming Growth Factor-β Signaling Does Not Abrogate Antiestrogen-induced Growth Inhibition of Human Breast Carcinoma Cells*

  1997cites this paper
• Transforming growth factor-beta system and its regulation by members of the steroid-thyroid hormone superfamily.

  1996cites this paper